---
title: Our Story - Eyerising International
description: The story of Eyerising International. From pioneering RLRL research to delivering myopia management solutions to children and families in over 30 countries worldwide.
image: https://eyerisinginternational.com/hubfs/eri-web/images/og-default.png
---

I am not an eye-care professional I am an eye-care professional

 Viewing the International site.

[![Eyerising International](https://eyerisinginternational.com/hubfs/eri-web/logo-white.png)](https://eyerisinginternational.com/?hsLang=en)

[Home](https://eyerisinginternational.com/?hsLang=en)

[About Us](https://eyerisinginternational.com/about?hsLang=en)

[About Eyerising](https://eyerisinginternational.com/about?hsLang=en) [Our Story](https://eyerisinginternational.com/story?hsLang=en) [Purpose, Mission & Values](https://eyerisinginternational.com/purpose?hsLang=en) [Our Team](https://eyerisinginternational.com/team?hsLang=en) [What is Myopia?](https://eyerisinginternational.com/myopia?hsLang=en) [Meet Willow](https://eyerisinginternational.com/willow?hsLang=en)

[Our Device](https://eyerisinginternational.com/device?hsLang=en)

[Our Device](https://eyerisinginternational.com/device?hsLang=en) [Safety Information](https://eyerisinginternational.com/safety?hsLang=en) [Regulatory](https://eyerisinginternational.com/regulatory?hsLang=en)

[News](https://eyerisinginternational.com/news?hsLang=en)

[Latest News](https://eyerisinginternational.com/news?hsLang=en) [Clinical Information](https://eyerisinginternational.com/clinical-info?hsLang=en) 

[Events](https://eyerisinginternational.com/events?hsLang=en)

[Contact](https://eyerisinginternational.com/contact?hsLang=en)

[Contact Us](https://eyerisinginternational.com/contact?hsLang=en) [Find a Clinic](https://eyerisinginternational.com/clinics?hsLang=en) [FAQs](https://eyerisinginternational.com/faqs?hsLang=en)

[Get in Touch](https://eyerisinginternational.com/contact?hsLang=en)

[Home](https://eyerisinginternational.com/?hsLang=en) [About Us](https://eyerisinginternational.com/about?hsLang=en) [Our Story](https://eyerisinginternational.com/story?hsLang=en) [Purpose, Mission & Values](https://eyerisinginternational.com/purpose?hsLang=en) [Our Team](https://eyerisinginternational.com/team?hsLang=en) [What is Myopia?](https://eyerisinginternational.com/myopia?hsLang=en) [Meet Willow](https://eyerisinginternational.com/willow?hsLang=en) [Our Device](https://eyerisinginternational.com/device?hsLang=en) [Safety Information](https://eyerisinginternational.com/safety?hsLang=en) [Regulatory Approval](https://eyerisinginternational.com/regulatory?hsLang=en) [News](https://eyerisinginternational.com/news?hsLang=en) [Clinical Information](https://eyerisinginternational.com/clinical-info?hsLang=en) [Events](https://eyerisinginternational.com/events?hsLang=en) [Contact Us](https://eyerisinginternational.com/contact?hsLang=en) [Find a Clinic](https://eyerisinginternational.com/clinics?hsLang=en) [FAQs](https://eyerisinginternational.com/faqs?hsLang=en) [Get in Touch](https://eyerisinginternational.com/contact?hsLang=en)

# Our Story

 From breakthrough research to a global mission.

## The Eyerising Journey

Foundation

### Founded by a World-Leading Researcher

 Professor Mingguang He, a globally recognised ophthalmologist and researcher, identified the therapeutic potential of repeated low-level red-light therapy for slowing myopia progression in children. His clinical insight laid the scientific foundation for what would become Eyerising.

Early Research

Technology

### Patented RLRL Technology

 The team secured patents for the proprietary repeated low-level red-light device and treatment protocol, protecting a novel approach to non-invasive myopia management that had not existed anywhere in the world.

Patent Secured

Evidence

### First Clinical Trials Demonstrate Efficacy

 Randomised controlled trials confirmed that RLRL therapy significantly reduces the rate of myopia progression in children, with results published in leading peer-reviewed ophthalmology journals. The clinical evidence base began to grow.

Clinical Trials

Global

### Eyerising International Established

 Eyerising International was established in Melbourne, Australia, with the mission of bringing RLRL therapy to families worldwide. Co-founded by Professor Mingguang He and Jason Sun, the company built a team of ophthalmologists, clinical experts, and MedTech executives.

Melbourne, Australia

Europe

### CE Marking for European Markets

 Eyerising achieved CE marking, enabling access to European markets and further demonstrating the device's compliance with international medical device safety and performance standards.

CE Marking

Regulatory

### Entering the Australian Market

 The Eyerising device was registered on the Australian Register of Therapeutic Goods (ARTG 412752), making it one of the first RLRL therapy devices to enter a global market outside of China.

ARTG 412752

Expansion

### Expanded to 40+ Countries Globally

 Eyerising International now operates across more than 40 countries, with over 1,500 active patients receiving RLRL therapy through a growing network of clinician partners in the Asia-Pacific, Europe, the Middle East, and beyond.

Today

## Our Mission

> “We see a world where myopia is controlled earlier, more easily, and more effectively.”

 At Eyerising International, our mission is to support eye-care professionals in managing your child’s myopia through our device. We work with clinicians and researchers around the world to make more myopia management options available for children. We are committed to providing parents and families with information, resources, and support so that decisions about children’s vision care are always guided by professional advice.

## Looking Ahead

 The myopia epidemic is accelerating. By 2050, an estimated 50% of the world's population is projected to be myopic.1 Eyerising International is committed to staying at the forefront of the scientific response to this global health challenge.

 We are actively expanding our clinical trial programme across multiple countries, deepening our evidence base, and continuing to improve the Eyerising device and patient experience. New regulatory approvals are underway in key markets, and our distributor network continues to grow.

 Our ambition is clear: to make effective, evidence-based myopia management accessible to every family that needs it, wherever they are in the world.

1 Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, Wong TY, Naduvilath TJ, Resnikoff S. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016 May;123(5):1036-42. doi: 10.1016/j.ophtha.2016.01.006.

## Be Part of the Story

 Whether you are a clinician, researcher, distributor, or parent, there is a role for you in advancing myopia management worldwide. 

[Get in Touch](https://eyerisinginternational.com/contact?hsLang=en)

![Eyerising International](https://eyerisinginternational.com/hubfs/eri-web/logo-white.png)

 Advancing myopia management through repeated low-level red-light therapy.

#### Company

- [About Us](https://eyerisinginternational.com/about?hsLang=en)
- [Our Team](https://eyerisinginternational.com/team?hsLang=en)
- [Our Story](https://eyerisinginternational.com/story?hsLang=en)
- [News](https://eyerisinginternational.com/news?hsLang=en)
- [Events](https://eyerisinginternational.com/events?hsLang=en)

#### Resources

- [Our Device](https://eyerisinginternational.com/device?hsLang=en)
- [Safety Information](https://eyerisinginternational.com/safety?hsLang=en)
- [Regulatory Approval](https://eyerisinginternational.com/regulatory?hsLang=en)
- [FAQs](https://eyerisinginternational.com/faqs?hsLang=en)
- [Find a Clinic](https://eyerisinginternational.com/clinics?hsLang=en)

#### Contact

 Suite 2.05, 9/11 Claremont St  
 South Yarra VIC 3141, Australia 

[info@eyerisinginternational.com](mailto:info@eyerisinginternational.com)

[LinkedIn](https://au.linkedin.com/company/eyerising-international)

THIS PRODUCT IS NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC

ALWAYS READ THE LABEL AND FOLLOW THE DIRECTIONS FOR USE

Ask your optometrist or ophthalmologist for advice to see if this product is right for your child.

Outcomes may vary for each patient. The Eyerising Myopia Management Device is exclusively available through eye care professionals (e.g. optometrists, ophthalmologists) for home use.

© 2026 Eyerising International. All rights reserved.

[LinkedIn](https://au.linkedin.com/company/eyerising-international) [Privacy Policy](https://eyerisinginternational.com/legal?hsLang=en) [Terms & Conditions](https://eyerisinginternational.com/legal?hsLang=en)

## Welcome to Eyerising International

To show you the most relevant information, please confirm which best describes you.

I am not an Eye-Care Professional

I am an Eye-Care Professional

## Disclaimer

This website is intended for use by eye care professionals only. By agreeing and proceeding, you are declaring you are a registered eye care professional. If you are not a registered eye care professional, do not proceed.

I Agree

I Disagree

```json
{
  "@context" : "https://schema.org",
  "@type" : "MedicalOrganization",
  "address" : {
    "@type" : "PostalAddress",
    "addressCountry" : "AU",
    "addressLocality" : "South Yarra",
    "addressRegion" : "VIC",
    "postalCode" : "3141",
    "streetAddress" : "Suite 2.05, 9/11 Claremont St"
  },
  "contactPoint" : {
    "@type" : "ContactPoint",
    "contactType" : "customer service",
    "email" : "info@eyerisinginternational.com"
  },
  "description" : "Australian MedTech company advancing repeated low-level red-light (RLRL) therapy for childhood myopia management.",
  "foundingDate" : "2020",
  "logo" : "https://43619611.fs1.hubspotusercontent-ap1.net/hubfs/43619611/eri-web/logo-white.png",
  "name" : "Eyerising International",
  "sameAs" : [ "https://www.linkedin.com/company/eyerising-international" ],
  "url" : "https://eyerisinginternational.com"
}
```